1[1]Endo A, Kuroda M, Tsujita Y. ML-236A, ML-236B and ML-236C, New inhibitors of cholesterogenesis produced by penicillium citrinum. J Antibiot, 1976, 29(12): 1346～1348
2[2]Endo A, Monacolink. A new hypocholesterolemic agent produced by a monascus species. J Antibiot, 1979, 32(8) :852～854
3[3]Alberts AW, Chen J, Kuron G, et al. Mevinolin:A highly potent competitive inhibitor of hydroxymethylglutaryl coenzyme-a reductase and a cholesterol lowering agent. Proc Natl Acad Sci USA, 1980, 77(12) :3957～3961
4[4]Serizawa N, Nakagawa K, Hanano K. Microbial hydroxylation of ML-236B (compaction) and monacolin K (MB-530B). J Antibiot, 1983, 36(5) :604～607
5[5]Tarr L. Pravastatin:A "new” advance in lipid therapy? Scrip, 1988, 1356:22～23
9[9]Haria M, Mctavish D. Pravastatin. Drugs, 1997, 53(2):299～311
10[10]Robert IL, August J, Fattu J. Fluvastatin: a quarter century of drug treatment of dyslipoproteinemia with a focus on the new HMG-CoA reductase inhibitor. Circulation, 1993, 87 (4, suppl): 45 ～ 49
5Karen L. Furie,Scott E. Kasner,Robert J. Adams,Gregory W. Albers,Ruth L. Bush,Susan C. Fagan,Jonathan L. Halperin,S. Claiborne Johnston,Irene Katzan,Walter N. Kernan,Pamela H. Mitchell,Bruce Ovbiagele,Yuko Y. Palesch,Ralph L. Sacco,Lee H. Schwamm,Sylvia Wassertheil-Smoller,Tanya N. Turan,Deidre Wentworth,李海峰(译),刘涛(译),杨潘(译),王鹏(译).卒中或短暂性脑缺血发作患者的卒中预防指南 美国心脏协会／美国卒中协会为医疗卫生专业人员制定的指南[J].国际脑血管病杂志,2011,19(1):1-49. 被引量：392
